Sunshine Biopharma FY2024 revenue $34.9M (+45% YoY); net loss widens to $5.1M

Sunshine Biopharma Inc.

2025-Q1 EPS reported -$0.44 revenue$8,901,341

Revenue $34.9M in FY2024, up 45% from $24.1M in FY2023; gross profit $10.7M.
Net loss $5.1M vs $4.5M in FY2023; G&A expenses $16.5M, up from $13.1M.
Completed ~$10M underwritten public offering for expansion of sales operations.
Launched 13 new generic drugs; received Health Canada approval for oncology drug NIOPEG.
Published PLpro inhibitor study in J. Med. Chem.; completed mouse model proof-of-concept for K1.1 mRNA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.